Ligand Pharmaceuticals Inc (LGND) · Oct 29, 2026 · Earnings
Beat — Adjusted EPS $2.67 vs ~$2.33 consensus
Ligand earnings beat Q3 estimates on a 51% royalty jump, though XOMA integration costs and investment losses pushed GAAP earnings negative.
Ligand is in the middle of becoming a larger royalty aggregator: the July XOMA acquisition more than doubled its portfolio to over 200 assets, adding commercial royalties and late-stage pipeline rights. This quarter is the first clear test of whether that scale is translating into recurring earnings rather than just a bigger asset base.
The core quarter beat expectations. Adjusted diluted EPS was $2.67 versus a published consensus of roughly $2.33, while total revenues and income were $78.7 million versus approximately $77 million expected. The beat came from the royalty engine: royalty revenue rose 51% year over year to $70.3 million, driven by XOMA assets and continued contribution from Filspari and Ohtuvayre.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Total revenues and income (Financial Statements) | $78.7M | $115.5M | ~$77.0M |
| Royalties (Financial Statements) | $70.3M | $46.6M | |
| Adjusted net income (Adjusted reconciliation) | $57.5M | $63.8M | |
| Adjusted diluted EPS (Adjusted reconciliation) | $2.67 | $3.09 | ~$2.33 |
The accounting headline is much weaker than the operating headline. GAAP swung to a $28.5 million loss, or $1.43 per share, because of $39.5 million in pre-tax investment losses, including a $35.7 million mark-to-market loss. That volatility obscures the underlying royalty performance, but it also means reported earnings remain heavily dependent on investment marks and acquisition-related adjustments.
XOMA is adding revenue but not yet cleanly adding profit. General and administrative expense jumped to $72.6 million from $28.4 million, with the filing pointing to XOMA transaction and integration costs, share-based compensation, and the larger portfolio-management platform. Adjusted EPS still declined 14% year over year, and adjusted net income fell 10%, because the royalty gains did not fully offset higher operating costs and the absence of the prior-year Pelthos income.
The balance sheet now supports more dealmaking, but with materially more leverage. Cash, cash equivalents and short-term investments fell to $447.4 million from $733.5 million at year-end, while convertible senior notes rose to $1.13 billion from $446.2 million. The company says it still has approximately $750 million of deployable capital including equity investments and credit-facility availability, and it is continuing to add assets through the Ryjunea royalty purchase and AvenCell financing.
The portfolio’s next proof points are increasingly regulatory and commercial, not just financial. The filing highlights a February 28, 2027 PDUFA date for Palvella’s Qtorin rapamycin and a planned December 8 investor day where Ligand expects to provide an updated five-year outlook.
Bottom line: This is a modest earnings beat that validates the XOMA-enhanced royalty engine, but not yet a clean profit acceleration story. The business is scaling faster than reported GAAP earnings, with integration costs and investment volatility still masking the improvement in recurring royalties.
Investor day and updated five-year outlook, December 8
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!